Interventions for Treating Intrahepatic Cholestasis in People with Sickle Cell Disease

Overview

Journal Cochrane Database Syst Rev

Publisher Wiley

Specialties General Medicine
Health Services

Date 2020 Jun 23

PMID 32567054

Citations 1

Authors

Arturo J Marti-Carvajal

Cristina Elena Marti-Amarista

Affiliations

Soon will be listed here.

Abstract

Background: Sickle cell disease is the most common hemoglobinopathy occurring worldwide and sickle cell intrahepatic cholestasis is a complication long recognized in this population. Cholestatic liver diseases are characterized by impaired formation or excretion (or both) of bile from the liver. There is a need to assess the clinical benefits and harms of the interventions used to treat intrahepatic cholestasis in people with sickle cell disease. This is an update of a previously published Cochrane Review.

Objectives: To assess the benefits and harms of the interventions for treating intrahepatic cholestasis in people with sickle cell disease.

Search Methods: We searched the Cystic Fibrosis and Genetic Disorders Group's Haemoglobinopathies Trials Register, which comprises references identified from comprehensive electronic database searches and handsearching of relevant journals and abstract books of conference proceedings. We also searched the LILACS database (1982 to 21 January 2020), the WHO International Clinical Trials Registry Platform Search Portal and ClinicalTrials.gov (21 January 2020). Date of last search of the Cochrane Cystic Fibrosis and Genetic Disorders Group's Haemoglobinopathies Trials Register: 25 November 2019.

Selection Criteria: We searched for published or unpublished randomised controlled trials.

Data Collection And Analysis: Each author intended to independently extract data, assess the risk of bias of the trials by standard Cochrane methodologies and assess the quality of the evidence using the GRADE criteria; however, no trials were included in the review.

Main Results: We did not identify any randomised controlled trials.

Authors' Conclusions: This updated Cochrane Review did not identify any randomised controlled trials assessing interventions for treating intrahepatic cholestasis in people with sickle cell disease. Randomised controlled trials are needed to establish the optimum treatment for this condition.

Citing Articles

Successful treatment of acute sickle cell intrahepatic cholestasis with therapeutic plasma exchange.

Tsitsikas D, Hall R, Meenan J, Orebayo F, Bello-Sanyaolu O, Badle S EJHaem. 2022; 2(1):118-120.

PMID: 35846083 PMC: 9175936. DOI: 10.1002/jha2.150.

References

Ware R, De Montalembert M, Tshilolo L, Abboud M . Sickle cell disease. Lancet. 2017; 390(10091):311-323. DOI: 10.1016/S0140-6736(17)30193-9. View

Modell B, Darlison M . Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ. 2008; 86(6):480-7. PMC: 2647473. DOI: 10.2471/blt.06.036673. View

Thorlund K, Anema A, Mills E . Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals. Clin Epidemiol. 2010; 2:57-66. PMC: 2943189. DOI: 10.2147/clep.s9242. View

Khurshid I, Anderson L, Downie G, Pape G . Sickle cell disease, extreme hyperbilirubinemia, and pericardial tamponade: case report and review of the literature. Crit Care Med. 2002; 30(10):2363-7. DOI: 10.1097/00003246-200210000-00029. View

SHEEHY T, Law D, Wade B . Exchange transfusion for sickle cell intrahepatic cholestasis. Arch Intern Med. 1980; 140(10):1364-6. View

Ebert E, Nagar M, Hagspiel K . Gastrointestinal and hepatic complications of sickle cell disease. Clin Gastroenterol Hepatol. 2010; 8(6):483-9. DOI: 10.1016/j.cgh.2010.02.016. View

Ioannidis J . Meta-research: The art of getting it wrong. Res Synth Methods. 2015; 1(3-4):169-84. DOI: 10.1002/jrsm.19. View

Baichi M, Arifuddin R, Mantry P, Bozorgzadeh A, Ryan C . Liver transplantation in sickle cell anemia: a case of acute sickle cell intrahepatic cholestasis and a case of sclerosing cholangitis. Transplantation. 2005; 80(11):1630-2. DOI: 10.1097/01.tp.0000184446.52454.69. View

Balshem H, Helfand M, Schunemann H, Oxman A, Kunz R, Brozek J . GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011; 64(4):401-6. DOI: 10.1016/j.jclinepi.2010.07.015. View

10.

Horn A, Freed N, Pecora A . Sickle cell hepatopathy: diagnosis and treatment with exchange transfusion. J Am Osteopath Assoc. 1987; 87(2):130-3. View

11.

Guyatt G, Oxman A, Kunz R, Atkins D, Brozek J, Vist G . GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol. 2011; 64(4):395-400. DOI: 10.1016/j.jclinepi.2010.09.012. View

12.

Kato G, Gladwin M . Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy. JAMA. 2008; 300(22):2638-46. PMC: 2756016. DOI: 10.1001/jama.2008.598. View

13.

Gluud C . "Negative trials" are positive!. J Hepatol. 1998; 28(4):731-3. DOI: 10.1016/s0168-8278(98)80301-2. View

14.

Guyatt G, Oxman A, Sultan S, Brozek J, Glasziou P, Alonso-Coello P . GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. J Clin Epidemiol. 2012; 66(2):151-7. DOI: 10.1016/j.jclinepi.2012.01.006. View

15.

Kaplan A . Complications of apheresis. Semin Dial. 2012; 25(2):152-8. DOI: 10.1111/j.1525-139X.2011.01026.x. View

16.

Theocharidou E, Suddle A . The Liver in Sickle Cell Disease. Clin Liver Dis. 2019; 23(2):177-189. DOI: 10.1016/j.cld.2018.12.002. View

17.

Ballas S, Kesen M, Goldberg M, Lutty G, Dampier C, Osunkwo I . Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management. ScientificWorldJournal. 2012; 2012:949535. PMC: 3415156. DOI: 10.1100/2012/949535. View

18.

Akinsheye I, Klings E . Sickle cell anemia and vascular dysfunction: the nitric oxide connection. J Cell Physiol. 2010; 224(3):620-5. DOI: 10.1002/jcp.22195. View

19.

Omata M, Johnson C, Tong M, TATTER D . Pathological spectrum of liver diseases in sickle cell disease. Dig Dis Sci. 1986; 31(3):247-56. DOI: 10.1007/BF01318115. View

20.

Wetterslev J, Thorlund K, Brok J, Gluud C . Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol. 2007; 61(1):64-75. DOI: 10.1016/j.jclinepi.2007.03.013. View